SCHEMBL21787578

SCHEMBL21787578

ISn1ccc2c1ncc1nccn12

nearest known ligand 0.33

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.33
MAP4K4 O95819 1/20 0.33
CSF1R P07333 1/20 0.33
PRKACA P17612 1/20 0.33
KDR P35968 1/20 0.33
CDK8 P49336 1/20 0.33
MAP2K1 Q02750 1/20 0.33
ACVR1 Q04771 1/20 0.33
MAP4K2 Q12851 1/20 0.33
ROCK1 Q13464 1/20 0.33
DYRK1A Q13627 1/20 0.33
AURKB Q96GD4 1/20 0.33
DYRK1B Q9Y463 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18767445 0.75 CDK8 (0.35) CHEK1MAP4K4CSF1RPRKACAKDR
SCHEMBL22891871 0.69 NOTUM (0.36) CHEK1MAP4K4CSF1RPRKACAKDR
SCHEMBL1417158 0.67 KDM4E (0.55) CHEK1MAP4K4CSF1RPRKACAKDR
SCHEMBL29965863 0.67 KDM4E (0.55) CHEK1MAP4K4CSF1RPRKACAKDR
SCHEMBL23546233 0.63 L3MBTL1 (0.52)
SCHEMBL18855535 0.63 DRD1 (0.31) CDK8ROCK1
SCHEMBL5098191 0.62 FGFR1 (0.38) CHEK1MAP4K4CSF1RPRKACAKDR
SCHEMBL2360060 0.62 DGAT1 (0.35)
SCHEMBL4602967 0.62 ALK (0.38) CHEK1MAP4K4CSF1RPRKACAKDR
SCHEMBL20759659 0.61 MGAM (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023131978-A1 IMPROVED PROCESS FOR THE PREPARATION OF UPADACITINIB MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2023-07-13 WO disclosed
EP-3845521-A2 SYNTHESIS METHODS FOR UPADACITINIB AND INTERMEDIATE THEREOF Suzhou Pengxu Pharmatech Co., Ltd. (CN) 2021-07-07 EP disclosed
WO-2021123288-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB CRYSTAL PHARMA, S.A.U. (ES) 2021-06-24 WO disclosed
WO-2020043033-A2 SYNTHESIS METHODS FOR UPADACITINIB AND INTERMEDIATE THEREOF 苏州鹏旭医药科技有限公司 2020-03-05 WO disclosed